Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines

BMC Cancer

Brian I Carr²  Aldo Cavallini²  Caterina Messa²  Nicola Carella²  Grazia Giannuzzi¹  Catia Lippolis²  Maria G Refolo²  Rosalba D’Alessandro² 

[1]Transfusion Medicine Center, “S. Maria degli Angeli” Hospital, via Cappuccini 7, 70017 Putignano, BA, Italy

[2]Laboratory of Biochemistry, National Institute for Digestive Diseases, IRCCS “Saverio de Bellis”, Via Turi 27, 70013, Castellana Grotte, BA, Italy

关键词: Invasion;    Growth;    Apoptosis;    HCC;    Platelets;    Regorefenib;   

Others  :  858807
DOI  :  10.1186/1471-2407-14-351

 received in 2013-12-30, accepted in 2014-05-19,  发布年份 2014

【 摘 要 】

Background

Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of Sorafenib or Regorafenib, two clinical HCC multikinase antagonists.

Methods

Several human HCC cell lines were grown in the presence and absence of Sorafenib or Regorafenib, with or without hPL. Growth was measured by MTT assay, apoptosis was assessed by Annexin V and by western blot, and autophagy and MAPK growth signaling were also measured by western blot, and migration and invasion were measured by standard in vitro assays.

Results

Both Sorafenib and Regorafenib-mediated inhibition of cell growth, migration and invasion were all antagonized by hPL. Drug-mediated apoptosis and decrease in phospho-ERK levels were both blocked by hPL, which also increased anti-apoptotic phospho-STAT, Bax and Bcl-xL levels. Preliminary data, obtained with epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I), included in hPL, revealed that these factors were able to antagonized Sorafenib in a proliferation assay, in particular when used in combination.

Conclusions

Platelet factors can antagonize Sorafenib or Regorafenib-mediated growth inhibition and apoptosis in HCC cells. The modulation of platelet activity or numbers has the potential to enhance multikinase drug actions.

【 授权许可】

   
2014 D’Alessandro et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Trousseau A: Phlegmana alba dolens. Clinic Med de l’Hotel-Dieu 1985, 3:654-712.
• [2]Levin J, Conley CL: Thrombocytosis associated with malignant disease. Arch Intern Med 1964, 114:497-500.
• [3]Leslie M: Cell biology: beyond clotting: the powers of platelets. Science 2010, 328:562-564.
• [4]Borsig L: The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008, 8:1247-1255.
• [5]Labelle M, Begum S, Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20:576-590.
• [6]Buergy D, Wenz F, Groden C, Brockmann MA: Tumor-platelet interaction in solid tumors. Int J Cancer 2012, 130:2747-2760.
• [7]Bambace NM, Holmes CE: The platelet contribution to cancer progression. J Thromb Haemost 2011, 9:237-249.
• [8]Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M: The platelet-cancer loop. Eur J Intern Med 2013, 24:393-400.
• [9]Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, et al.: Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012, 366:610-618.
• [10]Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
• [11]Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J: Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 2012, 36:192-200.
• [12]Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Burkart AL, Zhang K, Xing J, Yang H: Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer 2013, 44:293-304.
• [13]Yu D, Liu B, Zhang L: Platelet count predicts prognosis in operable non-small cell lung cancer. Exp Ther Med 2013, 5:1351-1354.
• [14]Wang H, Gao J, Bai M, Liu R, Li H, Deng T, Zhou L, Han R, Ge S, Huang D, Ba Y: The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer. Platelets 2013. doi:10.3109/09537104.2013.827782
• [15]Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, Chiang JH, Chau GY, Lui WY, Lee CC, Chang FY, Lee SD: Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004, 10:2472-2477.
• [16]Carr BI, Guerra V: Features of massive hepatocellular carcinomas. Eur J Gastroenterol Hepatol 2013. doi:10.1097/MEG.0b013e3283644c49
• [17]Carr BI, Guerra V: Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013, 58:1790-1796.
• [18]Carr BI, D’Alessandro R, Refolo MG, Lippolis C, Cavallini A, Messa C: Effects of Pheripheral Blood Platelets on HCC Cell Growth, Migration and Invasion. In The Liver Meeting Proc. Boston, MA, USA: AASLD; 2013.
• [19]Carr BI, Cavallini A, Lippolis C, D’Alessandro R, Messa C, Refolo MG, Tafaro A: Fluoro- Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013, 228:292-297.
• [20]D’Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI: Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 2013, 72:869-877.
• [21]Dashevsky O, Varon D, Brill A: Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer 2009, 124:1773-1777.
• [22]Demers M, Wagner DD: Targeting platelet function to improve drug delivery. Oncoimmunology 2012, 1:100-102.
• [23]Demers M, Ho-Tin-Noé B, Schatzberg D, Yang JJ, Wagner DD: Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res 2011, 71:1540-1549.
• [24]Song S, Wientjes MG, Gan Y, Au JL: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A 2000, 97:8658-8663.
• [25]Shen K, Cui D, Sun L, Lu Y, Han M: Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem 2012, 113:2086-2089.
• [26]Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG: Metformin: taking away the candy for cancer? Eur J Cancer 2010, 46:2369-2380.
• [27]Atzori F, Traina TA, Ionta MT, Massidda B: Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol 2009, 4:255-266.
• [28]Kina S, Phonaphonh T, Liang F, Kuang H, Arasaki A, Arakaki K, Nakasone T, Sunakawa H: PDGFα receptor is a mediator for cisplatin-induced Met expression. Eur J Pharmacol 2013, 699:227-232.
• [29]Zhou T, Duan J, Wang Y, Chen X, Zhou G, Wang R, Fu L, Xu F: Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol 2012, 33:1299-1306.
• [30]Peer D, Dekel Y, Melikhov D, Margalit R: Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 2004, 64:7562-7569.
• [31]Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
• [32]Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
• [33]Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N: The Bcl-xL inhibitor, ABT- 737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010, 52:1310-1321.
• [34]Galmiche A, Ezzoukhry Z, François C, Louandre C, Sabbagh C, Nguyen-Khac E, Descamps V, Trouillet N, Godin C, Regimbeau JM, Joly JP, Barbare JC, Duverlie G, Mazière JC, Chatelain D: BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res 2010, 8:1116-1125.
• [35]Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N: Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 2012, 131:548-557.
• [36]Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC, Galmiche A: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 2012, 131:2961-2969.
• [37]Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, Chauffert B, Galmiche A: Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer 2013, 133:1732-4172.
• [38]Liu Y, Liu A, Li H, Li C, Lin J: Celecoxib inhibits interleukin-6/interleukin-6 receptor- induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res (Phila) 2011, 4:1296-1305.
• [39]Dai Y, Grant S: Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007, 67:2908-2911.
• [40]Sitia G, Iannacone M, Guidotti LG: Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol 2013., 4doi:S0168- 8278(13)00373-5
• [41]Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S: Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013, 309:2563-2571.